Hagma H. Workel

Hagma H. Workel

Auto-generated profile, based on publicly available information

Hagma H. Workel

Department of Obstetrics and Gynecology, University Medical Centre Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
KBKoen Brummel
Koen Brummel
MRMarta Requesens
Marta Requesens
NRNienke van Rooij
Nienke van Rooij
HWHagma H. Workel
Hagma H. Workel
FEFlorine A. Eggink
Florine A. Eggink
MBMarco de Bruyn
Marco de Bruyn
Polymerase epsilon–mutant (POLE-mut) endometrial cancers are characterized by a near 100% disease-specific survival rate, even when treated with surgery alone. This survival, combined with the ultramutated genome and high level of neoantigens in these tumors, indicates a substantial degree of immune control in preventing disease spread and recurrence. Although these features are intriguing, the analysis of immune infiltration in POLE-mut endometrial cancers has predominantly been confined to IHC studies. In this study, we used single-cell RNA and T-cell receptor sequencing to characterize the immune landscape of POLE-mut endometrial cancers. Moreover, we analyzed patient blood samples taken 2 to 8 years after curative treatment to assess the formation of long-term immune memory in circulation. We identified specialized tumor-infiltrating myeloid subsets at different stages of maturation, an array of lymphocytes ranging from immature to cytotoxic, and adaptive NK cells, as well as tumor-reactive exhausted and effector T cells, all contributing to a highly inflammatory antitumor response. Our analysis of blood samples taken years after curative treatment uncovered the presence of tumor-reactive T-cell clones that matched the primary tumor. This indicates the formation of systemic long-term memory immune responses in POLE-mut endometrial cancer survivors. Our study highlights the distinctive immunogenicity of POLE-mut endometrial cancer and identifies key features associated with persistent antitumor immunity that may contribute to prolonged, relapse-free survival.

2 December 2025
Verified
Other
Open access
KBKoen Brummel
Koen Brummel
MRMarta Requesens
Marta Requesens
NRNienke van Rooij
Nienke van Rooij
HWHagma H. Workel
Hagma H. Workel
FEFlorine A. Eggink
Florine A. Eggink
MBMarco de Bruyn
Marco de Bruyn
Figure S3. Clonal expansion of T cells in POLE-mut EC patients.

2 December 2025
Verified
Other
Open access
KBKoen Brummel
Koen Brummel
MRMarta Requesens
Marta Requesens
NRNienke van Rooij
Nienke van Rooij
HWHagma H. Workel
Hagma H. Workel
FEFlorine A. Eggink
Florine A. Eggink
MBMarco de Bruyn
Marco de Bruyn
Figure S1. Relative tumor infiltrating immune cell populations in POLE-mut EC patients.


2 December 2025
Verified
Other
Open access
KBKoen Brummel
Koen Brummel
MRMarta Requesens
Marta Requesens
NRNienke van Rooij
Nienke van Rooij
HWHagma H. Workel
Hagma H. Workel
FEFlorine A. Eggink
Florine A. Eggink
MBMarco de Bruyn
Marco de Bruyn
Figure S5. Timeline of the patients used in the study.

2 December 2025
Verified
Other
Open access
KBKoen Brummel
Koen Brummel
MRMarta Requesens
Marta Requesens
NRNienke van Rooij
Nienke van Rooij
HWHagma H. Workel
Hagma H. Workel
FEFlorine A. Eggink
Florine A. Eggink
MBMarco de Bruyn
Marco de Bruyn
Polymerase epsilon–mutant (POLE-mut) endometrial cancers are characterized by a near 100% disease-specific survival rate, even when treated with surgery alone. This survival, combined with the ultramutated genome and high level of neoantigens in these tumors, indicates a substantial degree of immune control in preventing disease spread and recurrence. Although these features are intriguing, the analysis of immune infiltration in POLE-mut endometrial cancers has predominantly been confined to IHC studies. In this study, we used single-cell RNA and T-cell receptor sequencing to characterize the immune landscape of POLE-mut endometrial cancers. Moreover, we analyzed patient blood samples taken 2 to 8 years after curative treatment to assess the formation of long-term immune memory in circulation. We identified specialized tumor-infiltrating myeloid subsets at different stages of maturation, an array of lymphocytes ranging from immature to cytotoxic, and adaptive NK cells, as well as tumor-reactive exhausted and effector T cells, all contributing to a highly inflammatory antitumor response. Our analysis of blood samples taken years after curative treatment uncovered the presence of tumor-reactive T-cell clones that matched the primary tumor. This indicates the formation of systemic long-term memory immune responses in POLE-mut endometrial cancer survivors. Our study highlights the distinctive immunogenicity of POLE-mut endometrial cancer and identifies key features associated with persistent antitumor immunity that may contribute to prolonged, relapse-free survival.